在轻度认知障碍中识别帕金森症
Rishira Fernando1, Alan J Thomas1, Calum A Hamilton1
1Translational and Clinical Research Institute, Newcastle University, UK.
Journal of the neurological sciences
|February 29, 2024
概括
一个五项尺度有效地识别了轻度认知障碍 (MCI) 中的帕金森症. 与痴呆症相比,对于MCI建议使用较低的值,以提高临床帕金森症的诊断准确度.
科学领域:
- 神经学 神经学
- 认知科学 认知科学
背景情况:
- 临床帕金森症对于诊断莱维体轻度认知障碍 (MCI-LB) 至关重要.
- 在MCI中准确识别帕金森症可能具有挑战性.
- 来自统一帕金森病评分表 (UPDRS) 的五项评分表用于对痴呆症帕金森症的评估.
研究的目的:
- 评估五项UPDRS尺度在识别患有MCI的个体中帕金森症的有效性.
- 为了比较MCI与痴呆症的五项尺度的诊断性能.
主要方法:
- 两组MCI参与者 (n=146) 接受了体检,UPDRS评估和[123I]-FP-CIT SPECT成像.
- 参与者根据临床帕金森症 (P+/P-) 和多巴胺成像 (D+/D-) 进行分类.
- 五项尺度总结了UPDRS的休息震,勃拉迪基尼西亚,动作震,面部表情和性的得分.
主要成果:
- 五项尺度显示了高的诊断准确性 (AUROC 0.92-0.97) 区分P+D+从P-D-参与者跨队列.
- 在MCI中,3/4切割线实现了最佳灵敏度 (83-100%) 和特异性 (82-88%),超过了痴呆症衍生的7/8切割线.
- 该尺度在区分异常 (D+) 和正常 (D-) 多巴胺成像方面是无效的.
结论:
- 五项UPDRS尺度对于识别MCI的帕金森症是有效的.
- 较低的门值 (3/4) 更适合于MCI,而不是用于痴呆症的门值.
- 该尺度通过检测临床帕金森症来帮助诊断MCI-LB.
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K


